Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(apixaban)
3,205 results
  • Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study. [Journal Article]
    J Thromb Thrombolysis 2019Vedovati MC, Mosconi MG, … Becattini C
  • Rapidly available tests might be useful to measure the anticoagulant effect of direct oral anticoagulants (DOAs) in emergency situations as bleedings, surgery, or before thrombolysis. The aim of this study was to assess the effects of DOAs on global thromboelastometry (ROTEM). Coagulation parameters assessed at peak and trough in patients with non-valvular atrial fibrillation receiving apixaban, …
  • Direct oral anticoagulants: a review on the current role and scope of reversal agents. [Review]
    J Thromb Thrombolysis 2019Chaudhary R, Sharma T, … Gurbel P
  • New guideline recommendations prefer direct oral anticoagulants (DOACs) over warfarin in DOAC-eligible patients with atrial fibrillation and patients with venous thromboembolism. As expected with all antithrombotic agents, there is an associated increased risk of bleeding complications in patients receiving DOACs that can be attributed to the DOAC itself, or other issues such as acute trauma, inv…
  • Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation. [Journal Article]
    Europace 2019; 21(9):1297-1306Spinthakis N, Gue Y, … Gorog DA
  • CONCLUSIONS: Apixaban enhances endogenous fibrinolysis, with maximal effect in those with impaired fibrinolysis pre-treatment. Apixaban-treated patients exhibit more favourable fibrinolysis profiles than those taking warfarin or aspirin. Whether apixaban may confer additional thrombotic risk reduction in NVAF patients with impaired fibrinolysis, compared to warfarin, merits further study.
  • Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting. [Journal Article]
    Am J Health Syst Pharm 2019; 76(18):1395-1402Lacoste JL, Hansen CL
  • CONCLUSIONS: A review of current literature on antithrombotic therapy in patients with AF undergoing PCI and subsequent coronary artery stenting indicates that the favored regimen is dual therapy consisting of clopidogrel with rivaroxaban, apixaban, dabigatran, or a vitamin K antagonist. Aspirin may be used in the periprocedural period but should be discontinued thereafter to reduce the risk of bleeding. Decisions regarding specific agents and duration of treatment should be based on thrombotic risk, bleeding risk, and patient preference.
  • Bilateral Mechanical Thrombectomies for Simultaneous MCA Occlusions. [Journal Article]
    World Neurosurg 2019Storey C, Lebovitz J, … Jabbour P
  • CONCLUSIONS: The transient hypercoagulable state that was created with the withdrawal of apixaban likely increased our patient's risk of stroke. The literature supports continuing oral anticoagulants for endovascular procedures. The devasting consequences of thromboembolic events, whether stroke or pulmonary embolism can be catastrophic, but luckily, mechanical thrombectomy provides the means to minimize the morbidity and mortality from bilateral infarctions.
New Search Next